Best of the Week
Most Popular
1. The Trump Stock Market Trap May Be Triggered - Barry_M_Ferguson
2.Why are Central Banks Buying Gold and Dumping Dollars? - Richard_Mills
3.US China War - Thucydides Trap and gold - Richard_Mills
4.Gold Price Trend Forcast to End September 2019 - Nadeem_Walayat
5.Money Saving Kids Gardening Growing Giant Sunflowers Summer Fun - Anika_Walayat
6.US Dollar Breakdown Begins, Gold Price to Bolt Higher - Jim_Willie_CB
7.INTEL (INTC) Stock Investing to Profit From AI Machine Learning Boom - Nadeem_Walayat
8.Will Google AI Kill Us? Man vs Machine Intelligence - N_Walayat
9.US Prepares for Currency War with China - Richard_Mills
10.Gold Price Epochal Breakout Will Not Be Negated by a Correction - Clive Maund
Last 7 days
Is This Time Different? Predictive Power of the Yield Curve and Gold - 19th Aug 19
New Dawn for the iGaming Industry in the United States - 19th Aug 19
Gold Set to Correct but Internals Remain Bullish - 19th Aug 19
Stock Market Correction Continues - 19th Aug 19
The Number One Gold Stock Of 2019 - 19th Aug 19
The State of the Financial Union - 18th Aug 19
The Nuts and Bolts: Yield Inversion Says Recession is Coming But it May take 24 months - 18th Aug 19
Markets August 19 Turn Date is Tomorrow – Are You Ready? - 18th Aug 19
JOHNSON AND JOHNSON - JNJ for Life Extension Pharma Stocks Investing - 17th Aug 19
Negative Bond Market Yields Tell A Story Of Shifting Economic Stock Market Leadership - 17th Aug 19
Is Stock Market About to Crash? Three Charts That Suggest It’s Possible - 17th Aug 19
It’s Time For Colombia To Dump The Peso - 17th Aug 19
Gold & Silver Stand Strong amid Stock Volatility & Falling Rates - 16th Aug 19
Gold Mining Stocks Q2’19 Fundamentals - 16th Aug 19
Silver, Transports, and Dow Jones Index At Targets – What Direct Next? - 16th Aug 19
When the US Bond Market Bubble Blows Up! - 16th Aug 19
Dark days are closing in on Apple - 16th Aug 19
Precious Metals Gone Wild! Reaching Initial Targets – Now What’s Next - 16th Aug 19
US Government Is Beholden To The Fed; And Vice-Versa - 15th Aug 19
GBP vs USD Forex Pair Swings Into Focus Amid Brexit Chaos - 15th Aug 19
US Negative Interest Rates Go Mainstream - With Some Glaring Omissions - 15th Aug 19
GOLD BULL RUN TREND ANALYSIS - 15th Aug 19
US Stock Market Could Fall 12% to 25% - 15th Aug 19
A Level Exam Results School Live Reaction Shock 2019! - 15th Aug 19
It's Time to Get Serious about Silver - 15th Aug 19
The EagleFX Beginners Guide – Financial Markets - 15th Aug 19
Central Banks Move To Keep The Global Markets Party Rolling – Part III - 14th Aug 19
You Have to Buy Bonds Even When Interest Rates Are Low - 14th Aug 19
Gold Near Term Risk is Increasing - 14th Aug 19
Installment Loans vs Personal Bank Loans - 14th Aug 19
ROCHE - RHHBY Life Extension Pharma Stocks Investing - 14th Aug 19
Gold Bulls Must Love the Hong Kong Protests - 14th Aug 19
Gold, Markets and Invasive Species - 14th Aug 19
Cannabis Stocks With Millennial Appeal - 14th Aug 19
August 19 (Crazy Ivan) Stock Market Event Only A Few Days Away - 13th Aug 19
This is the real move in gold and silver… it’s going to be multiyear - 13th Aug 19
Global Central Banks Kick Can Down The Road Again - 13th Aug 19
US Dollar Finally the Achillles Heel - 13th Aug 19
Financial Success Formula Failure - 13th Aug 19
How to Test Your Car Alternator with a Multimeter - 13th Aug 19
London Under Attack! Victoria Embankment Gardens Statues and Monuments - 13th Aug 19
More Stock Market Weakness Ahead - 12th Aug 19
Global Central Banks Move To Keep The Party Rolling Onward - 12th Aug 19
All Eyes On Copper - 12th Aug 19
History of Yield Curve Inversions and Gold - 12th Aug 19
Precious Metals Soar on Falling Yields, Currency Turmoil - 12th Aug 19
Why GraphQL? The Benefits Explained - 12th Aug 19
Is the Stock Market Making a V-shaped Recovery? - 11th Aug 19
Precious Metals and Stocks VIX Are About To Pull A “Crazy Ivan” - 11th Aug 19
Social Media Civil War - 11th Aug 19
Gold and the Bond Yield Continuum - 11th Aug 19
Traders: Which Markets Should You Trade? - 11th Aug 19

Market Oracle FREE Newsletter

The No 1 Gold Stock for 2019

Amgen Onyx Deal, The Fastest Route To Biotech Profit Now

Companies / BioTech Aug 28, 2013 - 11:53 AM GMT

By: Money_Morning

Companies

Tara Clarke writes: On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal - making it the fifth-largest biotech deal in history according to Standard & Poor's Capital IQ.


The Amgen deal with Onyx highlights where insiders - and investors - see the best investments in the biotech industry.

I'm talking about cancer therapy - a multibillion dollar industry that will be the biggest M&A driver - and profit producer - for biotech investors.

In fact, Citigroup analysts estimate that the cancer immunotherapy market will generate $35 billion per year over the next 10 years as existing drugs grow market share and new therapies enter the market.

That means profits for anyone who picks the best investments to play this trend...

Booming Market for Cancer Therapy Drugs

Around 25% of biotech industry deals greater than $100 million presently involve cancer - more than any other disease, according to JPMorgan Chase & Co.

It's no wonder why there are so many zeros behind that estimate...

The American Cancer Society projects 1,660,290 Americans will be newly diagnosed with cancer in 2013. Of that group, 580,350 are projected to die of the disease; that's 1,600 people per day.

The fact is cancer remains the second-most common cause of death in the United States, accounting for almost one in every four deaths per year. The demand for a new wave of cancer treatments is in full throttle.

Enter Onyx.

The San Francisco-based biopharma specializes in developing therapies that target the molecular mechanisms that cause cancer.

Right now, it notably owns three anticancer treatments: Nexavar for liver and kidney cancer, Stivarga for colon cancer, and most famously Kyprolis, a last-ditch treatment of multiple myeloma (bone marrow cancer) that gained FDA approval last July.

Kyprolis has enjoyed $125 million in sales in the first six months of 2013. Analysts further project annual sales growing to $2 billion if the drug both gains approval overseas and can be used in earlier-stage treatments of the disease.

Meanwhile, Amgen's highest-grossing drugs are being threatened by new competition as their patents expire.

Enbrel, a rheumatoid arthritis treatment, grossed $1,075,249 in 2013 Q1 sales, but its patent expired in October 2012. The top-selling Neupogen and Neulasta franchise, which helps patients cope with the side effects of chemotherapy, facilitated $17.3 billion in Amgen revenue in 2012 alone. Both patents are due to expire in December.

Kyprolis is expected to buttress sales as its aging blockbusters prepare to face the open-market competition. Onyx should also help Amgen gain a higher profile in oncology, and its products play well with Amgen's existing cancer support medications.

"Amgen has a unique opportunity to add value to Kyprolis, a product which is at an early and promising stage of its launch," Robert A. Bradway, chief executive of Amgen, said in a statement Sunday.

Amgen will offer $125 per share in cash through a tender offer for Onyx's shares. The deal is expected to close at the beginning of the fourth quarter. For now, Onyx shares rose 5.58% to $123.49 and Amgen jumped 7.7% to $113.75.

And they aren't alone in delivering for shareholders - there are more of these best investments in the biotech M&A trend...

M&A Moves Create the New Best Biotech Investments

Large pharmaceutical companies have been seen increasingly looking to acquire smaller biotech firms to access new drugs and new patents, as they stand to experience significant revenue drops from expiring patents.

In fact, the volume of healthcare mergers and acquisitions went up 30% in the first half of 2013 when compared with the same period last year.

  • In May, pharmaceutical giant Actavis Inc. (NYSE: ACT) acquired specialty biotech Warner Chilcott (Nasdaq: WCRX) for $8.5 billion.
  • Celgene Corp. (Nasdaq: CELG) jumped into the blood cancer-drug arena last June by striking a licensing deal with MorphoSys AG (MPSYY). MorphoSys gets an up-front license fee of $92 million, and Celgene will purchase $60 million in new shares of the company.
  • GlaxoSmithKline (NSE: GLAXO) bought Human Genome Sciences (Nasdaq: HGSI) in July for $3 billion.
  • And on Aug. 19, Johnson & Johnson (NYSE: JNJ) completed its acquisition of Aragon Pharmaceuticals for $650 million up front, plus a potential $350 million in milestone bonuses. According to Johnson & Johnson, the deal was struck with the specific aim of strengthening Johnson's prostate cancer pipeline.

It's clear we're currently undergoing a "biotech buyout binge" driven by wealth-deflating patent expirations and a red hot cancer therapy industry.

Check out where the deal-making is driving up biotech stocks so that you can get ahead of the trend (and the crowd) to turn a profit. Money Morning Executive Editor William Patalon III shows you how in this special analysis for our Private Briefing investment service subscribers: How to Profit from Biotech Merger Mania

Source :http://moneymorning.com/2013/08/26/amgen-nasdaq-amgn-deal-shows-how-to-find-biotechs-best-investments/

Money Morning/The Money Map Report

©2013 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules